<DOC>
	<DOCNO>NCT01521780</DOCNO>
	<brief_summary>The purpose study characterize baseline variability panel tissue ( tumor adjacent ) blood-based biomarkers obtain participant hepatocellular carcinoma ( HCC ) . The primary hypothesis upper bound 80 % Confidence Interval log beta-catenin protein messenger RNA ( mRNA ) expression one core needle biopsy ( CNB ) equivalent = &lt; 0.65 .</brief_summary>
	<brief_title>Characterization Baseline Biomarker Variability Participants With Hepatocellular Carcinoma ( MK-0000-215 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Diagnosed HCC . Candidate surgical resection contraindication MRI procedure . Prior locoregional treatment tumor , unless untreated tumor present represent distinct untreated nodule . Confirmed suspect diagnosis fibrolamellar HCC , mixed HCC/cholangiocarcinoma metastatic tumor . Had liver transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>MRI</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>beta-catenin</keyword>
</DOC>